Outpatient 5-Fluorouracil, Folinic Acid and Cisplatin in Patients with Advanced Esophageal Carcinoma

Authors

  • Ellen Warner Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario (E. Warner, I.A. Kerr, G.A. Bjarnason), Cross Cancer Centre, Edmonton, Alberta (J.L. Jensen, A.L.A. Fields), the Division of Medical Oncology, Ottawa Regional Cancer Centre, Civic Division, Ottawa, Ontario (C. Cripps, R. Goel), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Manitoba (K.E. Khoo), and Wyeth-Ayerst Canada Inc. (A. Hrincu), Canada
  • Jorgen L. Jensen Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario (E. Warner, I.A. Kerr, G.A. Bjarnason), Cross Cancer Centre, Edmonton, Alberta (J.L. Jensen, A.L.A. Fields), the Division of Medical Oncology, Ottawa Regional Cancer Centre, Civic Division, Ottawa, Ontario (C. Cripps, R. Goel), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Manitoba (K.E. Khoo), and Wyeth-Ayerst Canada Inc. (A. Hrincu), Canada
  • Christine Cripps Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario (E. Warner, I.A. Kerr, G.A. Bjarnason), Cross Cancer Centre, Edmonton, Alberta (J.L. Jensen, A.L.A. Fields), the Division of Medical Oncology, Ottawa Regional Cancer Centre, Civic Division, Ottawa, Ontario (C. Cripps, R. Goel), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Manitoba (K.E. Khoo), and Wyeth-Ayerst Canada Inc. (A. Hrincu), Canada
  • Kong E. Khoo Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario (E. Warner, I.A. Kerr, G.A. Bjarnason), Cross Cancer Centre, Edmonton, Alberta (J.L. Jensen, A.L.A. Fields), the Division of Medical Oncology, Ottawa Regional Cancer Centre, Civic Division, Ottawa, Ontario (C. Cripps, R. Goel), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Manitoba (K.E. Khoo), and Wyeth-Ayerst Canada Inc. (A. Hrincu), Canada
  • Rakesh Goel Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario (E. Warner, I.A. Kerr, G.A. Bjarnason), Cross Cancer Centre, Edmonton, Alberta (J.L. Jensen, A.L.A. Fields), the Division of Medical Oncology, Ottawa Regional Cancer Centre, Civic Division, Ottawa, Ontario (C. Cripps, R. Goel), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Manitoba (K.E. Khoo), and Wyeth-Ayerst Canada Inc. (A. Hrincu), Canada
  • Ian A. Kerr Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario (E. Warner, I.A. Kerr, G.A. Bjarnason), Cross Cancer Centre, Edmonton, Alberta (J.L. Jensen, A.L.A. Fields), the Division of Medical Oncology, Ottawa Regional Cancer Centre, Civic Division, Ottawa, Ontario (C. Cripps, R. Goel), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Manitoba (K.E. Khoo), and Wyeth-Ayerst Canada Inc. (A. Hrincu), Canada
  • Georg A. Bjarnason Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario (E. Warner, I.A. Kerr, G.A. Bjarnason), Cross Cancer Centre, Edmonton, Alberta (J.L. Jensen, A.L.A. Fields), the Division of Medical Oncology, Ottawa Regional Cancer Centre, Civic Division, Ottawa, Ontario (C. Cripps, R. Goel), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Manitoba (K.E. Khoo), and Wyeth-Ayerst Canada Inc. (A. Hrincu), Canada
  • Anthony L. A. Fields Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario (E. Warner, I.A. Kerr, G.A. Bjarnason), Cross Cancer Centre, Edmonton, Alberta (J.L. Jensen, A.L.A. Fields), the Division of Medical Oncology, Ottawa Regional Cancer Centre, Civic Division, Ottawa, Ontario (C. Cripps, R. Goel), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Manitoba (K.E. Khoo), and Wyeth-Ayerst Canada Inc. (A. Hrincu), Canada
  • Angela Hrincu Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario (E. Warner, I.A. Kerr, G.A. Bjarnason), Cross Cancer Centre, Edmonton, Alberta (J.L. Jensen, A.L.A. Fields), the Division of Medical Oncology, Ottawa Regional Cancer Centre, Civic Division, Ottawa, Ontario (C. Cripps, R. Goel), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Manitoba (K.E. Khoo), and Wyeth-Ayerst Canada Inc. (A. Hrincu), Canada

DOI:

https://doi.org/10.1080/028418699431690

Abstract

In a multicenter phase II study, 30 patients with unresectable, locally advanced or metastatic squamous cell or adenocarcinoma of the esophagus were treated with folinic acid 200 mg/m2/d, 5-FU 300 mg/m2/d, and cisplatin 20 mg/m2/d intravenously for 5 days every 4 weeks. Two of 13 patients with squamous cell carcinoma (SCC) had a complete response (CR), but one died of pneumonia after 9 months while still in CR, and the other still in CR after more than 5 years. Six other patients (3 SCC, 2 of 16 with adenocarcinoma, 1 mixed histology) had a partial response with a median duration of 9 months (range 5 to 57+months) for an overall response rate of 27%. A further 6 patients (20%) had stable disease. Grade 4 neutropenia occurred in 6 patients (20%), with 5 requiring antibiotics for associated fever. Other grade 4 toxicities were nausea and vomiting (1), anemia (1), and thrombocytopenia (1); there were three early deaths (emphysema, cardiac arrest, pulmonary embolism). This combination appears to be an active, convenient regimen for advanced esophageal cancer, resulting in prolonged remission and survival in some patients.

Downloads

Download data is not yet available.

Downloads

Published

1999-01-01

How to Cite

Warner, E., Jensen, J. L., Cripps, C., Khoo, K. E., Goel, R., Kerr, I. A., … Hrincu, A. (1999). Outpatient 5-Fluorouracil, Folinic Acid and Cisplatin in Patients with Advanced Esophageal Carcinoma. Acta Oncologica, 38(2), 255–259. https://doi.org/10.1080/028418699431690